Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2026)

Barinthus Biotherapeutics has reported Assets Average for 6 years, with the latest figure at $95.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 37.05% year-over-year to $95.2 million; the trailing twelve-month figure through Mar 2026 stood at $95.2 million (down 37.05% YoY), and the FY2025 full-year result was $129.2 million, down 31.04% from the prior year.
• Assets Average for Q1 2026 stood at $95.2 million, down from $103.7 million in the prior quarter.
• The five-year high for Assets Average was $285.6 million in Q2 2022, with the low at $95.2 million in Q1 2026.
• Historically, Assets Average has averaged $204.1 million across 5 years, with a median of $207.0 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average soared 161.03% — and 2025, when it slumped 40.58%.
• Barinthus Biotherapeutics' Assets Average stood at $272.8 million in 2022, then decreased by 18.55% to $222.2 million in 2023, then retreated by 21.48% to $174.5 million in 2024, then plunged by 40.58% to $103.7 million in 2025, then slipped by 8.23% to $95.2 million in 2026.
• The last three Assets Average figures came in at $95.2 million (Q1 2026), $103.7 million (Q4 2025), and $119.4 million (Q3 2025), per Business Quant data.